Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer

DSpace/Manakin Repository

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer

Citable link to this page

 

 
Title: Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer
Author: Muralidhar, Vinayak; Xiang, Michael; Orio, Peter F.; Martin, Neil E.; Beard, Clair J.; Feng, Felix Y.; Hoffman, Karen E.; Nguyen, Paul L.

Note: Order does not necessarily reflect citation order of authors.

Citation: Muralidhar, Vinayak, Michael Xiang, Peter F. Orio, Neil E. Martin, Clair J. Beard, Felix Y. Feng, Karen E. Hoffman, and Paul L. Nguyen. 2016. “Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.” Journal of Contemporary Brachytherapy 8 (1): 1-6. doi:10.5114/jcb.2016.58080. http://dx.doi.org/10.5114/jcb.2016.58080.
Full Text & Related Files:
Abstract: Purpose Recent retrospective data suggest that brachytherapy (BT) boost may confer a cancer-specific survival benefit in radiation-managed high-risk prostate cancer. We sought to determine whether this survival benefit would extend to the recently defined favorable high-risk subgroup of prostate cancer patients (T1c, Gleason 4 + 4 = 8, PSA < 10 ng/ml or T1c, Gleason 6, PSA > 20 ng/ml). Material and methods We identified 45,078 patients in the Surveillance, Epidemiology, and End Results database with cT1c-T3aN0M0 intermediate- to high-risk prostate cancer diagnosed 2004-2011 treated with external beam radiation therapy (EBRT) only or EBRT plus BT. We used multivariable competing risks regression to determine differences in the rate of prostate cancer-specific mortality (PCSM) after EBRT + BT or EBRT alone in patients with intermediate-risk, favorable high-risk, or other high-risk disease after adjusting for demographic and clinical factors. Results: EBRT + BT was not associated with an improvement in 5-year PCSM compared to EBRT alone among patients with favorable high-risk disease (1.6% vs. 1.8%; adjusted hazard ratio [AHR]: 0.56; 95% confidence interval [CI]: 0.21-1.52, p = 0.258), and intermediate-risk disease (0.8% vs. 1.0%, AHR: 0.83, 95% CI: 0.59-1.16, p = 0.270). Others with high-risk disease had significantly lower 5-year PCSM when treated with EBRT + BT compared with EBRT alone (3.9% vs. 5.3%; AHR: 0.73; 95% CI: 0.55-0.95; p = 0.022). Conclusions: Brachytherapy boost is associated with a decreased rate of PCSM in some men with high-risk prostate cancer but not among patients with favorable high-risk disease. Our results suggest that the recently-defined “favorable high-risk” category may be used to personalize therapy for men with high-risk disease.
Published Version: doi:10.5114/jcb.2016.58080
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793071/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318700
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters